<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275766</url>
  </required_header>
  <id_info>
    <org_study_id>SNCTP610</org_study_id>
    <nct_id>NCT03275766</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders</brief_title>
  <official_title>Effects of Transcranial Magnetic Stimulation on Motor Symptoms of Patients With Psychiatric Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psychomotor slowing may occur in major psychiatric disorders, such as major depressive&#xD;
      disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills,&#xD;
      motor planning and gross motor behavior. In major depression and schizophrenia, psychomotor&#xD;
      slowing is associated with alterations of premotor cortex, dorsolateral prefrontal cortex and&#xD;
      basal ganglia. This randomized, sham-controlled, prospective trial will test, whether 15&#xD;
      sessions of repetitive transcranial magnetic stimulation (rTMS) may ameliorate psychomotor&#xD;
      slowing in schizophrenia or major depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psychomotor slowing may occur in major psychiatric disorders, such as major depressive&#xD;
      disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills,&#xD;
      motor planning and gross motor behavior. In major depression and schizophrenia, psychomotor&#xD;
      slowing is associated with alterations of premotor cortex, dorsolateral prefrontal cortex and&#xD;
      basal ganglia. This randomized, sham-controlled, prospective trial will test, whether 15&#xD;
      sessions of rTMS in 3 weeks may ameliorate psychomotor slowing in schizophrenia or major&#xD;
      depression.&#xD;
&#xD;
      Eligible participants will be randomized to one of four arms:&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">July 15, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Responders at Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>Number of participants with &gt;30% reduction from baseline in the Salpetriere Retardation Rating Scale, last observation carried forward method applied</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Salpetriere Retardation Rating Scale Total Score From Baseline to Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>observer based rating scale of the severity of psychomotor slowing, assessment blind to intervention Scores may range from 0 - 60, higher scores indicate worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Activity Level From Baseline to Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>actigraphically (wrist of the non-dominant arm) assessed motor activity during the wake periods of one day, given in counts/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Catatonia Severity From Baseline to Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>observer based rating of catatonia severity with the Bush Francis Catatonia Rating Scale, assessment blind to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fingertapping Score From Baseline to Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>Fingertapping test with the dominant and nondominant index finger for 10 sec, video-taped and blind assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coin Rotation From Baseline to Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>test of manual dexterity in both hands, rotation of a specified coin for 10 seconds, video-taped and blinded evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hand Gesture Performance From Baseline to Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>videotaped performance of hand gestures according to the Test of Upper Limb Apraxia (TULIA), blind evaluation and rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SANS Total Score From Baseline to Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>scale for the assessment of negative symptoms, applies to schizophrenia spectrum disorder patients, assessment blind to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From HAMD Total Score From Baseline to Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>Hamilton Rating Scale for Depression, 21-item version, applies to depression patients, assessment blind to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CAINS Total Score From Baseline to Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>the clinical assessment interview for negative symptoms, assessment blind to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PANSS Total and Subscores From Baseline to Week 3</measure>
    <time_frame>week 3</time_frame>
    <description>the positive and negative syndrome scale, interview to assess severity of schizophrenia symptoms, applies to schizophrenia spectrum disorder patients, assessment blind to intervention</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Psychomotor Retardation</condition>
  <condition>Psychomotor Slowing</condition>
  <condition>Schizophrenia and Related Disorders</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>DLPFC facilitatory</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC&#xD;
usually effective in depression treatment, probably no specific effect on psychomotor slowing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preSMA/SMA inhibitory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA&#xD;
should inhibit overactive premotor cortices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preSMA/SMA facilitatory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermittend theta burst stimulation (iTBS) over preSMA/SMA&#xD;
should facilitate neural activity within premotor cortices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham TMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham rTMS with a placebo coil over occipital cortex&#xD;
should have no effect at all (no transcranial magnetic stimulation, only sound)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DLPFC facilitatory</intervention_name>
    <description>15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
    <arm_group_label>DLPFC facilitatory</arm_group_label>
    <other_name>rTMS facilitatory DLPFC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SMA inhibitory</intervention_name>
    <description>1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
    <arm_group_label>preSMA/SMA inhibitory</arm_group_label>
    <other_name>rTMS inhibitory SMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SMA facilitatory</intervention_name>
    <description>Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli</description>
    <arm_group_label>preSMA/SMA facilitatory</arm_group_label>
    <other_name>iTBS facilitatory SMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham TMS</intervention_name>
    <description>Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session</description>
    <arm_group_label>sham TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  suffering from major depressive disorder or schizophrenia spectrum disorder according&#xD;
             to DSM-5 criteria&#xD;
&#xD;
          -  right handedness&#xD;
&#xD;
          -  normal or corrected-to-normal vision and hearing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  history of severe head trauma&#xD;
&#xD;
          -  current abuse of drugs or alcohol; past addiction to drugs or alcohol&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  incompatibility to cerebral MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Walther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern, University Hospital of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Psychiatry, University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <results_first_submitted>May 26, 2020</results_first_submitted>
  <results_first_submitted_qc>May 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2021</results_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bern</investigator_affiliation>
    <investigator_full_name>Sebastian Walther</investigator_full_name>
    <investigator_title>Prof. Dr., Head of the outpatient clinic, University Hospital of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03275766/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DLPFC Facilitatory</title>
          <description>repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC&#xD;
usually effective in depression treatment, probably no specific effect on psychomotor slowing&#xD;
DLPFC facilitatory: 15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
        </group>
        <group group_id="P2">
          <title>preSMA/SMA Inhibitory</title>
          <description>repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA&#xD;
should inhibit overactive premotor cortices&#xD;
SMA inhibitory: 1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
        </group>
        <group group_id="P3">
          <title>preSMA/SMA Facilitatory</title>
          <description>intermittend theta burst stimulation (iTBS) over preSMA/SMA&#xD;
should facilitate neural activity within premotor cortices&#xD;
SMA facilitatory: Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli</description>
        </group>
        <group group_id="P4">
          <title>Sham TMS</title>
          <description>sham rTMS with a placebo coil over occipital cortex&#xD;
should have no effect at all (no transcranial magnetic stimulation, only sound)&#xD;
sham TMS: Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>one subject randomized withdrew consent before the baseline assessments</population>
      <group_list>
        <group group_id="B1">
          <title>DLPFC Facilitatory</title>
          <description>repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC&#xD;
usually effective in depression treatment, probably no specific effect on psychomotor slowing&#xD;
DLPFC facilitatory: 15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
        </group>
        <group group_id="B2">
          <title>preSMA/SMA Inhibitory</title>
          <description>repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA&#xD;
should inhibit overactive premotor cortices&#xD;
SMA inhibitory: 1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
        </group>
        <group group_id="B3">
          <title>preSMA/SMA Facilitatory</title>
          <description>intermittend theta burst stimulation (iTBS) over preSMA/SMA&#xD;
should facilitate neural activity within premotor cortices&#xD;
SMA facilitatory: Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli</description>
        </group>
        <group group_id="B4">
          <title>Sham TMS</title>
          <description>sham rTMS with a placebo coil over occipital cortex&#xD;
should have no effect at all (no transcranial magnetic stimulation, only sound)&#xD;
sham TMS: Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="15.2"/>
                    <measurement group_id="B2" value="38.0" spread="15.6"/>
                    <measurement group_id="B3" value="34.2" spread="14.0"/>
                    <measurement group_id="B4" value="41.2" spread="15.3"/>
                    <measurement group_id="B5" value="39.5" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>major depression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>schizophrenia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Responders at Week 3</title>
        <description>Number of participants with &gt;30% reduction from baseline in the Salpetriere Retardation Rating Scale, last observation carried forward method applied</description>
        <time_frame>week 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DLPFC Facilitatory</title>
            <description>repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC&#xD;
usually effective in depression treatment, probably no specific effect on psychomotor slowing&#xD;
DLPFC facilitatory: 15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
          </group>
          <group group_id="O2">
            <title>preSMA/SMA Inhibitory</title>
            <description>repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA&#xD;
should inhibit overactive premotor cortices&#xD;
SMA inhibitory: 1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
          </group>
          <group group_id="O3">
            <title>preSMA/SMA Facilitatory</title>
            <description>intermittend theta burst stimulation (iTBS) over preSMA/SMA&#xD;
should facilitate neural activity within premotor cortices&#xD;
SMA facilitatory: Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli</description>
          </group>
          <group group_id="O4">
            <title>Sham TMS</title>
            <description>sham rTMS with a placebo coil over occipital cortex&#xD;
should have no effect at all (no transcranial magnetic stimulation, only sound)&#xD;
sham TMS: Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders at Week 3</title>
          <description>Number of participants with &gt;30% reduction from baseline in the Salpetriere Retardation Rating Scale, last observation carried forward method applied</description>
          <units>responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Salpetriere Retardation Rating Scale Total Score From Baseline to Week 3</title>
        <description>observer based rating scale of the severity of psychomotor slowing, assessment blind to intervention Scores may range from 0 - 60, higher scores indicate worse outcome</description>
        <time_frame>week 3</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Activity Level From Baseline to Week 3</title>
        <description>actigraphically (wrist of the non-dominant arm) assessed motor activity during the wake periods of one day, given in counts/h</description>
        <time_frame>week 3</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Catatonia Severity From Baseline to Week 3</title>
        <description>observer based rating of catatonia severity with the Bush Francis Catatonia Rating Scale, assessment blind to intervention</description>
        <time_frame>week 3</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fingertapping Score From Baseline to Week 3</title>
        <description>Fingertapping test with the dominant and nondominant index finger for 10 sec, video-taped and blind assessment</description>
        <time_frame>week 3</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Coin Rotation From Baseline to Week 3</title>
        <description>test of manual dexterity in both hands, rotation of a specified coin for 10 seconds, video-taped and blinded evaluation</description>
        <time_frame>week 3</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hand Gesture Performance From Baseline to Week 3</title>
        <description>videotaped performance of hand gestures according to the Test of Upper Limb Apraxia (TULIA), blind evaluation and rating</description>
        <time_frame>week 3</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SANS Total Score From Baseline to Week 3</title>
        <description>scale for the assessment of negative symptoms, applies to schizophrenia spectrum disorder patients, assessment blind to intervention</description>
        <time_frame>week 3</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From HAMD Total Score From Baseline to Week 3</title>
        <description>Hamilton Rating Scale for Depression, 21-item version, applies to depression patients, assessment blind to intervention</description>
        <time_frame>week 3</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CAINS Total Score From Baseline to Week 3</title>
        <description>the clinical assessment interview for negative symptoms, assessment blind to intervention</description>
        <time_frame>week 3</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PANSS Total and Subscores From Baseline to Week 3</title>
        <description>the positive and negative syndrome scale, interview to assess severity of schizophrenia symptoms, applies to schizophrenia spectrum disorder patients, assessment blind to intervention</description>
        <time_frame>week 3</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected during and after the daily rTMS sessions, inquiry covered the total three weeks of the trial</time_frame>
      <desc>inquiry with open questions</desc>
      <group_list>
        <group group_id="E1">
          <title>DLPFC Facilitatory</title>
          <description>repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC&#xD;
usually effective in depression treatment, probably no specific effect on psychomotor slowing&#xD;
DLPFC facilitatory: 15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
        </group>
        <group group_id="E2">
          <title>preSMA/SMA Inhibitory</title>
          <description>repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA&#xD;
should inhibit overactive premotor cortices&#xD;
SMA inhibitory: 1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli</description>
        </group>
        <group group_id="E3">
          <title>preSMA/SMA Facilitatory</title>
          <description>intermittend theta burst stimulation (iTBS) over preSMA/SMA&#xD;
should facilitate neural activity within premotor cortices&#xD;
SMA facilitatory: Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli</description>
        </group>
        <group group_id="E4">
          <title>Sham TMS</title>
          <description>sham rTMS with a placebo coil over occipital cortex&#xD;
should have no effect at all (no transcranial magnetic stimulation, only sound)&#xD;
sham TMS: Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Deterioration of psychiatric disorder</sub_title>
                <description>one patient experienced a deterioration of the underlying psychiatric disorder (major depression), which required short term hospitalization. The intervention was stopped. The problem resolved and the patient was discharged from the hospital.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>mild nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>altered visual perception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Sebastian Walther</name_or_title>
      <organization>University of Bern, University Hospital of Psychiatry, Bern</organization>
      <phone>+41 632 8979</phone>
      <email>sebastian.walther@upd.unibe.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

